Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2025)

Collegium Pharmaceutical has reported Gross Margin over the past 10 years, most recently at 62.49% for Q4 2025.

  • Quarterly results put Gross Margin at 62.49% for Q4 2025, up 847.0% from a year ago — trailing twelve months through Dec 2025 was 59.35% (down 1925.0% YoY), and the annual figure for FY2025 was 59.35%, down 41.0%.
  • Gross Margin for Q4 2025 was 62.49% at Collegium Pharmaceutical, up from 61.7% in the prior quarter.
  • Over the last five years, Gross Margin for COLL hit a ceiling of 1334.14% in Q1 2022 and a floor of 3.48% in Q4 2021.
  • Median Gross Margin over the past 5 years was 58.62% (2021), compared with a mean of 175.11%.
  • Biggest five-year swings in Gross Margin: soared 127076bps in 2022 and later plummeted -128067bps in 2023.
  • Collegium Pharmaceutical's Gross Margin stood at 3.48% in 2021, then skyrocketed by 1204bps to 38.41% in 2022, then surged by 65bps to 63.19% in 2023, then fell by -15bps to 54.02% in 2024, then increased by 16bps to 62.49% in 2025.
  • The last three reported values for Gross Margin were 62.49% (Q4 2025), 61.7% (Q3 2025), and 57.65% (Q2 2025) per Business Quant data.